Literature DB >> 32088366

Collection of Peripheral Blood Progenitor Cells in 1 Day Is Associated with Decreased Donor Toxicity Compared to 2 Days in Unrelated Donors.

Jack W Hsu1, Bronwen E Shaw2, Soyoung Kim3, Brent R Logan3, Jennifer A Sees4, Dennis L Confer5, Michael A Pulsipher6, Nirali Shah7, Galen E Switzer8, Muneer H Abidi9, Ibrahim A Ahmed10, Paulo N Anderlini11, Christopher Bredeson12, Saurabh Chhabra13, Christopher E Dandoy14, Miguel Angel Diaz15, Nosha Farhadfar16, Siddhartha Ganguly17, Usama Gergis18, Gregory A Hale19, Peiman Hematti20, Rammurti T Kamble21, Kimberly A Kasow22, Hillard M Lazarus23, Jane L Liesveld24, Hemant S Murthy25, Richard F Olsson26, Bipin N Savani27, Raquel Schears28, Sachiko Seo29, Melhern Solh30, Thomas Spitzer31, Amir Steinberg32, Michele Sugrue33, Phyllis Warkentin34, John R Wingard16.   

Abstract

Peripheral blood stem cells (PBSCs) have been increasingly used for allogeneic hematopoietic cell transplantation instead of bone marrow stem cells. Current National Marrow Donor Program policy recommends 5 days of daily filgrastim, followed by either 1 or 2 days of apheresis for unrelated donors, depending on collection center choice. To date, there are no published studies comparing the differences in donor experience between 1 day and 2 days of apheresis. We examined 22,348 adult unrelated donor collections in 184 centers between 2006 and 2016. Of these 22,348 donors, 20,004 (89.5%) had collection on 1 day, and the other 2344 (9.5%) had collection over 2 days. Information on why donors underwent apheresis in 1 day or 2 days was not available. Donors who underwent apheresis in 1 day were more likely to be male (67% versus 46%; P < .001), younger (age <30 years, 48% versus 36%; P < .001), and have a higher body weight (83.0 kg versus 75.9 kg; P< .001) and body mass index (BMI; >30, 30% versus 22%; P < .001). Successful collection of the requested CD34+ cell count was achieved on the first day in 82% of 1-day collections and in 16% of 2-day collections. Despite not administering filgrastim the evening after the first day of collection in patients who underwent 2 days of apheresis, the median concentration of CD34+ cells/L in the product was higher on the second day of apheresis compared with the first day (23.8 × 106 CD34+/L on day 1 versus 28.7 × 106 CD34+/L on day 2; P< .001). Donors who underwent collection in 1 day were less likely to experience citrate toxicity (36% versus 52%; P< .001), hospitalization (1% versus 6%; P< .001), and other side effects related to apheresis (Modified Toxicity Criteria incidence: 20% versus 26%; P < .001). Female sex, older age, collection via central lines, and higher BMI were factors associated with greater likelihood for the development of toxicity, whereas less toxicity was noted in those with higher CD34+ counts and more blood processed on the first day of collection. We conclude that although unrelated donors can be successfully collected in 1 day or 2 days, 1-day apheresis procedures were associated with less overall toxicity, and thus we recommend single-day collections, especially if the requested number of cells have been collected in 1 day.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Keywords:  Apheresis; Donor toxicity; Unrelated donor

Year:  2020        PMID: 32088366      PMCID: PMC7347029          DOI: 10.1016/j.bbmt.2020.02.011

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  19 in total

1.  A cell-kinetic model of CD34+ cell mobilization and harvest: development of a predictive algorithm for CD34+ cell yield in PBPC collections.

Authors:  A Humpe; J Riggert; I Meineke; M Kurz; A Eil; B Storkebaum; C Binder; U Munzel; I Funke; P Höcker; M Wiesneth; M Köhler
Journal:  Transfusion       Date:  2000-11       Impact factor: 3.157

2.  Large-volume leukapheresis using femoral venous access for harvesting peripheral blood stem cells with the Fenwal CS 3000 Plus from normal healthy donors: predictors of CD34+ cell yield and collection efficiency.

Authors:  Sang Kyun Sohn; Jong Gwang Kim; Yeo Soo Chae; Dong Hwan Kim; Nan Young Lee; Jang Soo Suh; Kyu Bo Lee
Journal:  J Clin Apher       Date:  2003       Impact factor: 2.821

3.  Kinetic study of CD34+ cells during peripheral blood stem cell collections.

Authors:  P Bojko; W Stellberg; C Küdde; M Scharifi; M Herrmann; S Mayer; A Harstrick; S Seeber
Journal:  J Clin Apher       Date:  1999       Impact factor: 2.821

4.  Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3928 donors.

Authors:  Kristina Hölig; Michael Kramer; Frank Kroschinsky; Martin Bornhäuser; Thilo Mengling; Alexander H Schmidt; Claudia Rutt; Gerhard Ehninger
Journal:  Blood       Date:  2009-08-07       Impact factor: 22.113

5.  Peripheral blood stem cell donation: an analysis from the International Bone Marrow Transplant Registry (IBMTR) and European Group for Blood and Marrow Transplant (EBMT) databases.

Authors:  P Anderlini; J D Rizzo; M L Nugent; N Schmitz; R E Champlin; M M Horowitz
Journal:  Bone Marrow Transplant       Date:  2001-04       Impact factor: 5.483

6.  Prospective evaluation of cell kinetics, yields and donor experiences during a single large-volume apheresis versus two smaller volume consecutive day collections of allogeneic peripheral blood stem cells.

Authors:  Charles D Bolan; Charles S Carter; Robert A Wesley; Yu Ying Yau; A John Barrett; Richard W Childs; Elizabeth J Read; Susan F Leitman
Journal:  Br J Haematol       Date:  2003-03       Impact factor: 6.998

7.  Lower risk for serious adverse events and no increased risk for cancer after PBSC vs BM donation.

Authors:  Michael A Pulsipher; Pintip Chitphakdithai; Brent R Logan; Willis H Navarro; John E Levine; John P Miller; Bronwen E Shaw; Paul V O'Donnell; Navneet S Majhail; Dennis L Confer
Journal:  Blood       Date:  2014-04-15       Impact factor: 22.113

8.  Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor.

Authors:  W I Bensinger; C H Weaver; F R Appelbaum; S Rowley; T Demirer; J Sanders; R Storb; C D Buckner
Journal:  Blood       Date:  1995-03-15       Impact factor: 22.113

9.  Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts.

Authors:  M Körbling; D Przepiorka; Y O Huh; H Engel; K van Besien; S Giralt; B Andersson; H D Kleine; D Seong; A B Deisseroth
Journal:  Blood       Date:  1995-03-15       Impact factor: 22.113

10.  Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program.

Authors:  Michael A Pulsipher; Pintip Chitphakdithai; John P Miller; Brent R Logan; Roberta J King; J Douglas Rizzo; Susan F Leitman; Paolo Anderlini; Michael D Haagenson; Seira Kurian; John P Klein; Mary M Horowitz; Dennis L Confer
Journal:  Blood       Date:  2009-02-03       Impact factor: 22.113

View more
  1 in total

1.  Transplantation of allogeneic cryopreserved hematopoietic cell grafts during the Covid-19 pandemic: A National Marrow Donor Program perspective.

Authors:  Steven M Devine
Journal:  Am J Hematol       Date:  2020-12-02       Impact factor: 13.265

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.